ReviewFrontiers in oncology2026
Efficacy comparison of radical antegrade modular pancreatosplenectomy versus conventional distal pancreatectomy in the treatment of left-sided pancreatic cancer: a meta-analysis and systematic review.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the efficacy and safety of radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatectomy (CDP) for left-sided pancreatic cancer. Methods: Computerized searches were conducted in PubMed, Embase, Cochrane Library, CNKI, Wanfang Data and other Chinese and English databases to collect studies comparing RAMPS with CDP for left-sided pancreatic cancer published from January 2003 to October 2025. Two researchers independently completed literature screening and data extraction; the ROBINS-I tool was used for bias risk assessment; RevMan 5.4.1 software was used for effect size combination, and R software was used for sensitivity analysis and publication bias analysis. Result: A total of 21 studies were included, involving 2,591 patients, among which 9 were propensity score-matched (PSM) studies. The results of the meta-analysis showed that compared with CDP, RAMPS could significantly increase the R0 resection rate (RR = 1.10, 95% CI: 1.03-1.18, P = 0.007) and the number of lymph nodes dissected (MD = 3.58, 95%CI 1.66 - 5.50, P<0.001). However, substantial heterogeneity was noted for these outcomes (I2 = 72%/93%). No significant differences were found in operative time, blood loss, hospital stay, overall complication rates, or perioperative mortality. Crucially, there were no significant differences in overall survival (HR = 0.93, 95% CI: 0.76-1.13, P = 0.46) or disease-free survival (HR = 1.01, 95% CI: 0.77-1.33, P = 0.92) between the two procedures. Conclusion: For left-sided pancreatic cancer, RAMPS may offer advantages in local tumor control and surgical radicality; however, such advantages have not been shown to translate into meaningful improvements in survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.